四甲基吡嗪对实验性大鼠肝纤维化防治作用的研究  

Effects of prevention aad treatment of tetramethylpyrazine on experimental liver fibrosis in rats

作　　者：李善高[1,2] 王天才[1,2] 梁扩寰[1,2] 程向东 

机构地区：[1]同济医科大学同济医院 [2]湖北江汉油田第二医院

出　　处：《中华消化杂志》1998年第3期153-155,共3页Chinese Journal of Digestion

基　　金：卫生部临床科重点建设项目

摘　　要：目的评价四甲基吡嗪对肝纤维化的防治作用。方法以大白鼠为实验对象，采用６０％四氯化碳皮下注射，按每１００ｇ体重０．３ｍｌ，每３日１次，共２３次，诱导肝纤维化模型。四甲基吡预防组和治疗组大鼠分别于第１次、第１０次注射四氯化碳时开始给四甲基吡，按每１００ｇ体重１０ｍｇ灌胃，１日１次。实验第１０周抽血检测血清中ＰＣ－Ⅲ、ＨＡ、ＬＮ含量，取肝组织作肝内胶原定量分析。结果四甲基吡嗪预防组ＰＣ－Ⅲ、ＨＡ、ＬＮ及肝内胶含量与正常对照组比较。差异无显著性（Ｐ＞０．０５）。四甲基吡治疗组上述四项指标虽高于正常对照组。但明显低于葡萄糖组和肝纤维化模型组（Ｐ＜０．０１）。结论四甲基吡嗪对实验性肝纤维化有防治作用。Objective The purpose of this study was to investigate whether tetramethylpyrazine (TMP) can prevent and delay the development of liver fibrosis in rats. Method Hepatofibrosis model was induced by injecting 60% CCl4 3ml/100g body weight subscutaneously once very three days for ten weeks. Rats in TMP prevention group were given TMP (10mg/100g/day) at the first injection of CCl4. Rats in TMP treatment group were given TMP (10mg/100g/day) at the tenth injection of CCl4. All rats were killed at the end of the tenth weeks. The level of serum procollagen type-Ⅲ(PC-Ⅲ), hyaluronate acid (HA), laminin(LN), the contents of liver collagen were detected respectively . Results No significant difference was noted in the concentration of PC- Ⅲ , HA, LN and the content of liver collagen between the TMP prevention group and the control group (P>0.05). Although the concentration of PC-Ⅲ ,HA,LN and the level of liver collagen were higher in TMP treatment group than those in the control group (P<0.05), it was much lower in the TMP treatment group than that in the control group and the hepatofibrosis model gruop (P<0.01). Conclusion The TMP can prevent and delay the development of hepatofibrosis induced by CCl4.

关 键 词：四甲基吡嗪 肝纤维化 防治 

分 类 号：R575.201[医药卫生—消化系统]